Citadel Advisors
ANVS icon

Citadel Advisors’s Annovis Bio ANVS Stock Holding History

Citadel Advisors’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Sell
46,600
-115,900
-71% -$318K ﹤0.01% 11987
2025
Q4 		$562K Buy
162,500
+53,300
+49% +$160K ﹤0.01% 8748
2025
Q3 		$226K Buy
109,200
+76,200
+231% +$190K ﹤0.01% 10996
2025
Q2 		$71.6K Sell
33,000
-15,600
-32% -$30.8K ﹤0.01% 11570
2025
Q1 		$72.9K Buy
48,600
+33,600
+224% +$103K ﹤0.01% 11861
2024
Q4 		$75.5K Sell
15,000
-2,800
-16% -$20.3K ﹤0.01% 11859
2024
Q3 		$143K Sell
17,800
-134,700
-88% -$1.26M ﹤0.01% 10620
2024
Q2 		$878K Buy
152,500
+64,200
+73% +$520K ﹤0.01% 6856
2024
Q1 		$1.05M Buy
88,300
+33,100
+60% +$361K ﹤0.01% 6811
2023
Q4 		$1.03M Buy
+55,200
New +$489K ﹤0.01% 6612

Other funds holding ANVS

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Citadel Advisors's ANVS Position: Q4 2025 in Review

Citadel Advisors sold out of Annovis Bio (ANVS) in Q4 2025, closing a stake of 174,345 shares — an estimated $524K sold.

Citadel Advisors first reported a position in ANVS in Q1 2021 and held it in 8 quarters. The position peaked at $1.18M in Q3 2021. 53 funds tracked by Wall St. Rank hold ANVS as of Q4 2025.

  • Citadel Advisors reported no remaining Annovis Bio position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 174,345 Annovis Bio shares in Q4 2025, an estimated $524K.
  • Citadel Advisors first reported a position in Annovis Bio in Q1 2021 and held it in 8 quarters.
  • Citadel Advisors's Annovis Bio position peaked at $1.18M in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Annovis Bio as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.